Bronchiectasis is usually classified as cystic fibrosis (CF) related or CF unrelated (non-CF); the latter is not considered an orphan disease any more, even in developed countries. Irrespective of the underlying etiology, bronchiectasis is the result of interaction between host, pathogens, and environment. Vitamin D is known to be involved in a wide spectrum of significant immunomodulatory effects such as down-regulation of pro-inflammatory cytokines and chemokines. Respiratory epithelial cells constitutively express 1α-hydroxylase leading to the local transformation of the inactive 25(OH)-vitamin D to the active 1,25(OH)2-vitamin D. The latter through its autocrine and paracrine functions up-regulates vitamin D dependent genes with important consequences in the local immunity of lungs. Despite the scarcity of direct evidence on the involvement of vitamin D deficiency states in the development of bronchiectasis in either CF or non-CF patients, it is reasonable to postulate that vitamin D may play some role in the pathogenesis of lung diseases and especially bronchiectasis. The potential contribution of vitamin D deficiency in the process of bronchiectasis is of particular clinical importance, taking into consideration the increasing prevalence of vitamin D deficiency worldwide and the significant morbidity of bronchiectasis. Given the well-established association of vitamin D deficiency with increased inflammation, and the indicative evidence for harmful consequences in lungs, it is intriguing to speculate that the administration of vitamin D supplementation could be a reasonable and cost effective supplementary therapeutic approach for children with non-CF bronchiectasis. Regarding CF patients, maybe in the future as more data become available, we have to re-evaluate our policy on the most appropriate dosage scheme for vitamin D.
Core tip: Vitamin D deficiency seems to be associated with respiratory health. Herein, we present the experimental and epidemiological data that imply a role of vitamin D deficiency in the development of cystic fibrosis (CF) and non-CF bronchiectasis. Numerous experimental data provide insight to the mechanism by which vitamin D modulates immunity, and therefore its deficiency may enhance the susceptibility to infectious diseases and affect the control of inflammation process. Epidemiological data provide evidence for the association of vitamin D deficiency and bronchiectasis, either directly or indirectly, through its relation with the risk for respiratory tract infections. This knowledge is of interest for the pediatrician as vitamin D supplementation may be a future candidate therapeutic option for bronchiectasis.
In 1922, vitamin D was identified as a nutrient, derived from cod, shark and burbot liver oil, which promoted calcium deposition in the bones of rachitic rats. In 1925, it was found that vitamin D is mainly synthesized in the skin by the transformation of 7-dehydrocholesterol upon exposure to sunlight[2,3]. Nowadays, it is well known that the main source of vitamin D is the skin through the transformation of its precursor, 7-dehydrocholesterol by ultraviolet B radiation. Only tiny amounts are ingested from the usual diet, with the exception of fish oil and dairy products fortified with vitamin D.
Vitamin D is hydroxylated in the liver by mitochondrial 25-hydroxylase enzyme to 25(OH) vitamin D [25(OH)D, calcidiol], and then an amount of this compound undergoes a further conversion to 1,25(OH)2 vitamin D [1,25(OH)2D, calcitriol] by the kidney enzyme 25-hydroxyvitamin D-1-α hydroxylase (1α-hydroxylase). The latter is encoded by the gene CYP27B1. Additionally, the mitochondrial enzyme 25-hydroxyvitamin D-24 hydroxylase produces the inactive forms 24,25(OH)2D and 1,24,25(OH)3D using as substrates the 25(OH)D and 1,25(OH)2D, respectively[5,6].
1,25(OH)2D and 25(OH)D are the most biologically active and the major circulating forms of vitamin D, respectively[7,8]. The relatively stable metabolite 25(OH)D and, to some extent, 1,25(OH)2D are bound to the vitamin D binding protein (VDBP). In total, 99% of circulating vitamin D compounds are bound either to the VDBP or, to a lesser degree, to albumin and lipoproteins.
The serum levels of the 25(OH)D reflect the vitamin’s body stores are used to determine its status. Calcitriol is not an adequate status indicator as it has short half life and its synthesis depends mainly on homeostatic regulation mechanisms and not on 25(OH)D levels[12,13]. The deficiency and insufficiency status of vitamin D are generally defined by 25(OH)D serum levels < 20 ng/mL and 20-30 ng/mL, respectively. Using these definitions it has been estimated that about 1 billion people worldwide have either vitamin D deficiency or insufficiency, with children and adolescents being at high risk for vitamin D deficiency. However, the definition of the different states of vitamin D status is not unambiguous and it remains a matter of debate among scientists.
To date, calcitriol is considered a hormone with endocrine actions that are not limited to calcium and phosphorus homeostasis and bone turnover, as it was initially thought. For the exertion of most of its biological actions calcitriol, interacts with the nuclear vitamin D receptor (VDR) which belongs to the superfamily of nuclear receptors for steroid hormones. As early as 1979, it was shown in a rat model that receptors of calcitriol exist in target tissues that were not known to participate in vitamin D metabolism until then. The first time the extra-skeletal effects of vitamin D were observed was in early 80’s, with the reports of differentiation-inducing effect of 1,25(OH)2D3 in mouse leukemia and human myeloid leukemia cells[17,18]. Thus far, it is recognized that VDRs are present in several (but not in all) tissues throughout the body such as skin, placenta, pancreas, breast, prostate, and immunity cells[7,19]. Additionally, it was shown that 1,25(OH)2D can also be produced extrarenally as 1α-hydroxylase has been isolated in different tissues and cells such as prostate, breast, colon, lung, skin, pancreatic β cells, immune cells (including alveolar macrophages, dentritic cells and lymphocytes), and airway epithelia[10,20]. Extrarenally produced 1,25(OH)2D has autocrine and paracrine functions inhibiting cell proliferation, promoting cell differentiation, regulating apoptosis and modulating immune responses.
Since the discovery that VDRs, and 1α-hydroxylase are present in several tissues and in different types of cells, several research efforts, either experimental or epidemiological, have been performed aiming to understand the biological significance of these findings. There is now a growing body of evidence suggesting that vitamin D may have a role in the evolvement of different diseases such as malignant, autoimmune, infectious, cardiovascular, and lung disorders. More specifically, it seems that vitamin D through the modulation of immune and inflammatory responses may be involved in the pathophysiology of several respiratory disorders such as asthma, cystic fibrosis (CF), chronic obstructive lung diseases, cancer, respiratory infections, interstitial lung diseases and bronchiectasis[12,22–26]. Respiratory epithelial cells constitutively express 1α-hydroxylase leading to the local transformation of the inactive 25(OH)D to the active 1,25(OH)2D. This active form of vitamin D exerts its autocrine/paracrine function upregulating vitamin D dependent genes with important consequences in the local immunity of lungs. It is reasonable therefore to postulate that vitamin D may play some role in the pathogenesis of lung diseases and especially bronchiectasis.
The aim of the current review is to present the existing scientific information on the possible association of vitamin D with bronchiectasis, related or not to CF. The potential contribution of vitamin D deficiency in the process of bronchiectasis is of particular clinical importance, taking into consideration the increasing prevalence of vitamin D deficiency worldwide and the significant morbidity of bronchiectasis, especially among children of socially disadvantaged populations.
Bronchiectasis is a word of Greek origin and means dilated bronchi. This condition was first described in pathological specimens in 1819 by Rene Laennec, who also invented the stethoscope. The term was used to describe dilated and inflamed bronchi according to the pathological findings.
Thirty years ago, bronchiectasis in children was considered an orphan disease. Since then, and especially after bronchography was superseded by high resolution computed tomographic scanning (HRCT) as the most commonly used technique for diagnosis, it has been recognized that the burden of bronchiectasis in childhood is low but not negligible. However, the etiology is now different from that noted in the 50’s when symptoms of bronchiectasis usually started after pertussis or measles. Bronchiectasis nowadays is classified as either related or unrelated to CF, with the latter defined as non-CF bronchiectasis. The etiology of non-CF pediatric bronchiectasis is only remotely associated with vaccine preventable diseases such as measles or pertussis. There are several original studies and reviews in the literature that discuss the etiology of pediatric non-CF bronchiectasis. A recent systematic review of 989 affected subjects from twelve relevant studies summarized the available information of cases diagnosed by chest computed tomography. Infectious diseases, such as pneumonia, measles, tuberculosis, varicella, accounted for 19% of non-CF pediatric bronchiectasis followed by primary immunodeficiency (17%), aspiration/foreign body (10%), and primary ciliary dyskinesia (7%). No causal association was identified in about a third of cases.
In the guidelines published by the Thoracic Society of Australia and New Zealand, the prerequisites for clinical suspicion of the syndrome in children is: (1) persistent wet cough not responding to four weeks of antibiotics; (2) more than three episodes of wet cough per year responding to antibiotics and lasting more than four weeks; or (3) a persisting for more than six weeks chest radiograph abnormality despite the appropriate treatment.
As it has already been mentioned, HRCT is now the gold standard for the diagnosis of bronchiectasis[33,34]. As it was shown by Grenier et al in an adult population, using as diagnostic standard the bronchographic findings, HRCTs with 1.5 mm section thickness at 10 mm intersection spacing, attained a sensitivity of 96% and specificity of 93% regarding the detection of bronchiectasis. Eastham et al studied retrospectively 93 children with HRCT confirmed bronchiectasis and found that they constituted 9.6% of all new referrals to their tertiary pediatric respiratory center; this number represented a 10-fold higher rate of the respective diagnosis prior to the introduction of HRCT scanning. It is therefore plausible to assume that the introduction of HRCT scanning has contributed significantly to the recognition of the true burden of bronchiectasis in childhood. Furthermore, Eastham et al showed that HRCT diagnosed bronchiectasis in children is not always irreversible; it may progress to established bronchiectasis, but it may also return to a pre-bronchiectatic stage, or even resolve entirely. It is therefore conceivable that the early recognition of bronchiectasis and the prompt initiation of the appropriate treatment are of great importance in order to prevent the establishment of irreversible lesions.
Cystic fibrosis is the most common lethal, autosomal recessive disorder, among Caucasians. It is due to mutations in a gene called cystic fibrosis transmembrane conductance regulator (CFTR) that encodes chloride channels called CFTR proteins; bronchial epithelial cells, express CFTR proteins in their apical membranes. Pathologic CFTR mutations impair the production of the corresponding protein and therefore, there is dysregulation of ion movement in the bronchial surface, excessive absorption of airway surface liquid, and dehydration and hyperviscosity of airway secretions. The latter remain stagnant, form mucus plugs and obstruct bronchial lumen. The ensuing defective mucocilliary clearance favours the intraluminal survival and proliferation of bacteria, and leads in chronic endobronchial infection[39–41]. Chronic infection induces a persistent and intense inflammatory response in the airways characterized by abundance of neutrophils. The main proinflammatory mediators involved in the recruitment of neutrophils are interleukin (IL)-1β, tumour necrosis factor α, leukotriene β4, and especially some cytokines of the CXC chemokine family, particularly CXCL8 (also known as IL-8). Neutrophils generate cytokines, oxidants and proteases, such as neutrophilic elastase. The produced proteases are so abundant that overpower the antiprotease protection of the lung[40,43,44]. However, despite extensive mobilization of the lung’s defensive mechanisms, infection cannot be eradicated from the airways. On the contrary, it persists and deteriorates progressively, leading to worsening of chronic inflammation, further impairment of mucociliary clearance, and permanent presence of bacteria growing in biofilm structures. Collectively, these events represent a vicious cycle that results in progressive destruction of the airways and will eventually lead to bronchiectasis and respiratory failure. In addition to the above described sequence of detrimental events there is also evidence suggesting that mutations of the CFTR gene, can have a direct deleterious impact on airway immunity, through dysregulation of inflammatory mediators production, ineffective airway inflammation, and modification of responses to pathogens[40,45].
Common features between CF and non-CF bronchiectasis and a possible role for vitamin D in disease pathogenesis
Irrespective of its underlying etiology, bronchiectasis is the result of the interaction between host, pathogens and environment. Dysregulated host immune responses, airway inflammation and the presence of pathogens contribute to the pathophysiology of bronchiectasis. The current concept on the pathogenesis of bronchiectasis in children is the “vicious circle hypothesis”. The vicious circle may begin with any event that impairs mucociliary clearance and permits the establishment of bacterial “colonisation” in the lower airways, and hence predisposes to bioﬁlm formation. What it follows is a period of persistent bacterial bronchitis, which acts as the driving force for the chronic inﬂammation, and finally creates sufﬁcient bronchial damage to appear as bronchiectasis on a CT scan. The initial impairment to mucociliary clearance may be due to various reasons, such as a viral lower respiratory tract infection that destroys cilia which may take many weeks before fully recover; airway inflammation and mucus plugging as in asthma; dehydration of the peri-ciliary liquid and mucus as in CF; structural obstruction as in tracheomalacia and foreign body aspiration; microaspirations and impaired cough in children with serious neurological impairments; or is in itself secondary to bacterial infections in patients with signiﬁcant immunodeﬁciencies.
Vitamin D, as it was aforementioned, may have anti-infective and anti-inflammatory properties and therefore may play some role in the pathogenesis of the disease. For this reason, the host immune and inflammatory responses in CF and non-CF bronchiectasis in relation to vitamin D status, as well as its potential link with respiratory tract infections, will be presented in the following sections.
VITAMIN D AND IMMUNITY
The presence of VDR in cells of the innate immune system, such as dendritic cells, peripheral blood mononuclear cells, activated T lymphocytes, and even quiescent CD4 T cells[49,50] along with the presence in macrophages and dendritic cells of the enzymes responsible for activation and degradation of vitamin D (1a-hydroxylase, and 25-hydroxyvitamin D-24-hydroxylase, respectively), implies that vitamin D has an active part in innate immunity. Indeed, several studies have shown that vitamin D possesses a modulatory function exerted in a number of ways, some of which will be discussed below. Antimicrobial activity of innate immunity is influenced by vitamin D through the induction in monocytes, skin, and lung, of cathelicidin[52,53] which is an antimicrobial peptide having a central role in host defense against bacterial infections[54,55]. It is most likely that vitamin D inhibits the growth of bacteria in the airways through cathelicidin. It is known that the ability of CF airway epithelia to kill bacteria is impaired. The antibacterial activity of CF bronchial cells against Pseudomonas aeruginosa can be partially restored through cathelicidin induction after treatment with 1,25(OH)2D[57,58]. Besides, cathelicidin expression in the airways is associated with local – but not serum – levels of vitamin D[59,60], and bronchial cells with mutated CFTR have a decreased ability to activate vitamin D. Collectively, the above results may suggest that vitamin D up-regulates activity of cathelicidin, and perhaps of other innate immunity components, in response to bronchial bacterial infections. This up-regulation seems to be impaired in CF airways due to inadequate local activation of vitamin D.
The immune stimulus per se can affect local 25(OH) D metabolism as it is suggested by the increase in 1a-hydroxylase mRNA expression and 1,25(OH)2D synthesis of respiratory epithelial cells, after stimulation of Toll-like receptor-3 by viral RNA. The above evidence strongly supports the hypothesis that a local pro-inflammatory microenvironment can influence vitamin’s D metabolism. This fascinating phenomenon has been described in patients suffering from Crohn’s disease; however, up to now, there are no studies examining the effects of chronic endobronchial infection on the local metabolism of vitamin D.
Dendritic cells have a critical role in innate immunity and can promote the differentiation of naïve CD4+ T cells to either effector or regulatory T-cells (Treg). vitamin D can affect the stimulatory characteristics of DCs and change the balance towards the induction of CD4+CD25+Foxp3+ Treg. It can also enhance recruitment of Treg cells at inﬂammatory sites. This suppressive, anti-inflammatory function of vitamin D may contribute to the limitation of chronic bronchial inflammation and have a beneficial effect in the control of the disease.
Vitamin D also plays a role in modifying adaptive immunity while it is not yet clear if it moves the balance towards Th1 or Th2 response. The literature has provided us with a surge of evidence, though sometimes the results are conflicting. Thus, it was demonstrated that the administration of vitamin D decreased Th1 cytokine secretion and inhibited T-cell proliferation[64,65]. Vitamin D was also shown to either inhibit or enhance Th2 cell differentiation and production of Th2 cytokines. In another study on human cord naive CD4 and CD8 T cells it was demonstrated that vitamin D exhibits an inhibitory effect on IFN-γ production through IL-12, and it can also suppress IL-4, and IL-13 expression induced by IL-4. Matheu et al found that the administration of vitamin D in rodents could induce IL-4, IL-5, and IL-13. However, Jorde et al study on the effects of vitamin D administration in obese humans did not corroborated the previous result. Vitamin D supplementation did not induce Th2 responses in vivo whereas, on the other hand, proinflammatory TH17 responses were blocked by administration of vitamin D in mice and humans[70–72]. Regarding B cells, it is known that treatment with 1,25(OH)2D hinders proliferation and differentiation to IgG secreting plasma cells. Although there are enough data to recognize the impact of vitamin D in adaptive immunity, the picture becomes less clear when considering the direct consequences in CF and non-CF bronchiectasis. There are only some sparse data indirectly relating the immunological effects of vitamin D with bronchiectasis. Vitamin D reduces the expression in Th17 cells of IL-17, which is a cytokine found elevated in the sputum and the lungs of CF patients[74,75]. Aspergillus fumigatus, has been implicated as a common cause of both CF and non-CF bronchiectasis. Recently, it was shown that CF patients with allergic bronchopulmonary aspergillosis (ABPA) had increased Th2 reactivity, and this was associated with lower serum vitamin D levels. When 1,25(OH)2D was added to CD4+ T cells isolated from these patients, the induction of IL-5 and IL-13 by Aspergillus decreased and Th2 responses of CD4+ T cells were reduced. Aspergillus-induced lung inflammation in CF was further studied by Coughlan et al who demonstrated that Aspergillus bronchial colonization can increase Th2 cytokine production, through down-regulation of VDR expression. This down-regulation could be reversed with itraconazole treatment of Aspergillus. The authors suggested that supplementation of vitamin D could probably have a useful therapeutic effect in preventing ABPA on condition that there would be concurrent elimination of Aspergillus to permit VDR expression.
INDIRECT EVIDENCE IMPLYING A ROLE OF VITAMIN D IN THE PATHOGENESIS OF BRONCHIECTASIS
Relation between vitamin D and lung disease: Experimental and epidemiological data
Despite the knowledge gained over the years on the role of vitamin D in musculoskeletal system, the existing evidence over its effects in the pathogenesis and outcome of CF and non-CF bronchiectasis is sparse. There are some interesting data however implying a pathogenetic role of vitamin D insufficiency in the induction of damage in lung tissue.
The main reasoning behind this hypothesis is that lung is deprived of the vitamin’s anti-inflammatory capacity. Vitamin D down-regulates cytokines and chemokines that promote tissue destruction, and are found in abundance in CF and non-CF bronchiectatic lungs[22,78]. It was shown that CF respiratory epithelial cells and macrophages incubated with 1,25(OH)2D displayed a significant down-regulation in the neutrophil-attracting chemokine, IL-8[79,80], and that high doses of cholecalciferol (250000 IU) in adults hospitalized with pulmonary exacerbation of CF resulted in a reduction in the serum levels of IL-6 and TNF-α.
The anti-inflammatory activity of vitamin D may originate from the promotion of anti-inflammatory/regulatory cytokines secretion, such as IL-10. However, the mechanisms involved in up-regulation of anti-inflammatory and down-regulation of pro-inflammatory cytokines may not be simply due to the 1,25(OH)2D binding to vitamin D Response Elements (VDRE), which are specific upstream sequences in gene promoters that activate gene transcription. They may also occur through other indirect modulatory routes acting through signaling proteins that control the expression of anti- and pro-inflammatory cytokines.
MAPK phosphatase 1 (MKP-1), is such an example; the enzyme is an inhibitor of pro-inflammatory signaling and contains VDRE within its gene promoter. It is known to be up-regulated by either 25(OH)D or 1,25(OH)2D, in a dose-dependent manner. 1,25(OH)2D induces the expression of MKP-1 in human monocytes. In blood mononuclear cells isolated from asthmatic patients, baseline MKP-1 mRNA was associated with serum 25(OH)D levels. Also, in patients not treated with inhaled steroids, dexamethasone-induced MKP-1 expression increased with higher 25(OH)D levels. These results imply that local 1,25(OH)2D production may increase MKP-1 expression[78,84].
Other likely mechanisms implicated in cytokine suppression may include VDRE-independent inhibition of a major pro-inflammatory factor, namely nuclear-factor kappa B (NF-κB). 1,25(OH)2D has been associated with a significant decline in translocation of NF-κB into the nucleus, possibly through the stimulation of IκB-α (the inhibitor of NF-κB) by 1,25(OH)2D[19,85]. 1,25(OH)2D has been shown to modulate IκB-α through either transcriptional or transcription-independent mechanisms, resulting in an increase of mRNA expression of IκB-α and stabilization of IκB-α protein[86,87]. The above data are summarized in Table Table11.
In two retrospective studies vitamin D insufficiency was found to be correlated with the severity of lung disease in CF children. Simoneau et al observed that vitamin D insufficiency was associated with Pseudomonas bronchial infection, and McCauley et al observed that 25(OH)D levels were negatively associated with the rate of pulmonary exacerbations in children, and positively with FEV1 in adolescents. The results from some studies in CF patients indicate towards an association between low 25(OH)D levels and declining lung function. However, this finding was not universal, and has not been confirmed in children[81,89–93]. The effects of vitamin D in the lung function of adults, but not pediatric, CF patients may suggest that vitamin D deficiency exerts greater influence on CF lungs as the disease progresses. A reduction in the strength of respiratory muscles has been proposed as a likely mechanism, though there is no evidence to prove it. Furthermore, the relation might not be causal since the severity of lung disease may result in the sequence of reduced physical activity, less sun exposure, and decrease in serum 25(OH)D levels.
Vitamin D and respiratory tract infection: Epidemiological studies
Bacterial bronchial infection constitutes an integral part in the pathogenesis of bronchiectasis, although it has also been suggested that resident microbiota as well as viral and other infections (mycobacteria) are among the pathogens of the vicious cycle of bronchiectasis pathophysiology. It is has been well known since 1959 that the majority of children with bronchiectasis grew some pathogen in their sputum cultures. Recent bronchoalveolar lavage studies have shown that the most commonly isolated pathogens in children with non-CF bronchiectasis are non typeable Haemophilus influenza, Streptococcus pneumonia, Moraxella catarrhalis, and to a lesser extent Staphylococcus aureus and Pseudomonas.aeruginosa[31,36,94].
Vitamin D deficiency is related with the risk of lung infections and may be implicated in the bronchiectasis development and progression through this pathway. The first example of a possible association between vitamin D deficiency and an infectious disease was tuberculosis. It was in 1848, prior to the discovery of vitamin D, when in a study held in a London hospital, 1000 patients with tuberculosis were given either the usual care for the disease, or care plus cod liver oil three times a day. About a third of patients in the control group deteriorated or died compared to only a fifth of those on cod-liver oil. Since 1980, many studies investigated a possible association of tuberculosis and vitamin D deficiency. A meta-analysis conducted in 2008 by Nnoaham et al showed that low serum vitamin D levels were associated with increased risk for active tuberculosis. Although this meta-analysis included studies with only adult subjects, it was also shown in two later studies that serum vitamin D levels were lower in children with latent or active tuberculosis compared to the non-infected controls[98,99].
Similarly, it has been demonstrated that vitamin D deficiency is related with the risk for acute respiratory tract infection. It was in 1975 when Salimpour found that 43% of 200 rachitic children suffered from bronchopneumonia, a finding that he characterized as unexpected. Later, it was corroborated by other investigators that children with rickets were at increased risk for developing respiratory infectious disease[101,102]. Muher et al found that, after correcting for confounders, there was a 13-fold increased incidence of rickets among Ethiopian children hospitalized with pneumonia compared to controls. The results of another study from Jordan pointed to the same direction. More specifically, 85% of the rachitic infants were admitted due to lower respiratory tract infections compared to only 30% of the control non-rachitic group. In two other studies from the Indian subcontinent it was found that serum vitamin D levels in non-rachitic children with lower respiratory tract infection were significantly lower compared to healthy controls[103,104]. This finding, however, was not confirmed by other investigators. It is of interest however, that McNally et al who found no association between 25(OH) vitamin D levels and risk of hospitalization for acute lower tract infection (bronchiolitis or pneumonia), observed that vitamin D deficiency influenced disease severity. More specifically, the children with acute lower tract infection who were eventually admitted to the pediatric intensive care unit, had significantly lower serum vitamin D levels compared to either the rest of the group with milder respiratory infection or the control group with no respiratory infection.
A systematic review of observational studies that was conducted by Jolliffe et al showed that there was a significant association between low vitamin D status and the risk for acute respiratory tract infections in subjects of all ages (children and adults). On the other hand, they found that the randomized controlled clinical trials, which investigated the protective role of vitamin D supplementation from respiratory tract infections, did not point to the same direction. They attributed this inconsistency to the heterogeneity of the included trials regarding both the dose of vitamin D supplementation and the baseline levels of vitamin D prior to the intervention. Bergman et al conducted a similar meta-analysis and found that vitamin D supplementation had a protective effect against acute respiratory infection in subjects of all ages (6 mo-75 years). However, they recognized as limitations of their meta-analysis the heterogeneity of included studies and the high likelihood of publication bias. Another systematic review that included only randomized controlled pediatric trials failed to show a significant association between vitamin D supplementation and risk for acute respiratory infection. The researchers emphasized that their results should be interpreted with caution due to the small number and heterogeneity of included studies. It seems therefore that although many studies have revealed an association between vitamin D deficiency and risk for acute respiratory infection the data are not sufficient enough to support supplementation with vitamin D as a preventive measure to lower this risk.
As calcitriol exerts most of its biological actions via binding to the VDR, the possibility that VDR polymorphisms were associated with the risk of respiratory infections was also explored by a number of investigators[109–111]. The majority of studies were performed in children with RSV bronchiolitis and it was suggested that there was a positive association between the Fokl minor allele (ff) and susceptibility to RSV bronchiolitis. This association seems to be biologically plausible since f allele encodes a less active VDR that may affect the final activity of calcitriol. More recently, a VDR polymorphism was found to be associated with the susceptibility to community acquired pneumonia as well as with the disease severity in Chinese children.
VITAMIN D AND BRONCHIECTASIS: CLINICAL STUDIES AND CHALLENGES
To the best of our knowledge, there are no clinical studies directly exploring the presumed link between vitamin D deficiency and CF or non-CF bronchiectasis, in children. However, there is a case control study in adults with non-CF bronchiectasis. More specifically, Chalmers et al showed that 50% of patients with bronchiectasis were vitamin D deficient and 43% insufficient, and these percentages were significantly higher in comparison with the control group. They also found that vitamin D deficient patients were more commonly colonized with bacteria. Vitamin D deficient patients had lower FEV1, more frequent pulmonary exacerbations, higher sputum levels of inflammatory markers (myeloperoxidase, neutrophil elastase, IL-8) and demonstrated a more rapid decline in lung function over 3 years follow-up. However, the assessment of LL-37 levels in airways, and neutrophil phagocytosis either revealed a significant difference to the opposite direction of the initial hypothesis, or they failed to show any difference. Therefore, the authors were not able to provide an explanation on the hypothesized mechanism, namely, the implication of vitamin D deficiency in bronchiectasis severity.
Another small study in patients with primary cilia dyskinesia (PCD) showed that 79% of patients with bronchiectasis had vitamin D deficiency or insufficiency. However, 72% of the total population had also vitamin D deficiency or insufficiency, and there was no difference between PCD patients with and without bronchiectasis in vitamin D levels. The study may have failed to provide clear results because of its small sample size.
The paucity of studies prevents firm conclusions on the association between vitamin D deficiency and CF or non-CF bronchiectasis. And what is more, some authors have even expressed doubts on the anti-inflammatory of vitamin D. Among other things, it has been argued that vitamin D is primarily synthesized in the skin through the exposure to UV radiation and therefore it may simply be a surrogate of sunlight exposure. As it is well known, UV radiation has immunomodulatory properties in itself, irrespective of the UV-synthesized vitamin D. It has also been speculated that the observed low vitamin D levels could be a direct consequence of reduced outdoor physical activity of patients with chronic lung diseases such as bronchiectasis[114,116]. This very important issue, to the best of our knowledge, has not been examined as a confounder in any of the relevant studies. Another issue that has been discussed in the literature is whether 25(OH)D could be a negative acute phase reactant and therefore its values may not be a reliable indicator of vitamin D status in inflammatory conditions[118,119].
VITAMIN D AS A THERAPEUTIC POTENTIAL IN BRONCHIECTATIC LUNG DISEASE
Given the well-established association of vitamin D deficiency with increased inflammation, and the indicative evidence for harmful consequences in lungs, it is intriguing to speculate that the administration of vitamin D supplementation could be a reasonable and cost effective supplementary therapeutic approach for children with non-CF bronchiectasis. Vitamin D (as well as the rest of lipid-soluble vitamins), in doses sufficient to achieve serum levels > 30 ng/mL, has been part of the standard treatment for CF since many decades ago.
Vitamin D desirable serum levels reflect our current knowledge on preserving bone health. However, the issue of dose will become much more complex if we consider administering vitamin D for lung diseases, since we have to take into account the – yet unknown – levels required for its extra-skeletal functions. To make matters more complicated, a given dose of vitamin D will not necessarily attain the same increase of 25(OH)D serum levels in all patients. The required daily doses to reach optimal levels for bone health, vary greatly in patients ranging from 400 to 5000 IU daily. The dose needed in order to attain the vitamin’s maximum immune-modulatory function is probably higher than the dose required for optimal bone health. Based on currently available data, 1,25(OH)2D exerts its immune-modulatory functions at concentrations ranging from 10-100 nmol/L, which are much higher than the usually observed serum levels of 100 to 135 pmol/L. This apparent paradox is due to the fact that vitamin D function in tissues is exerted mainly by the locally-produced 1,25(OH)2D. Indeed, lung epithelial cells express high levels of 1a-hydroxylase and are able of producing locally high levels of 1,25(OH)2D. When these cells were supplemented with 1 mmol/L of 25(OH)D, they produced 600 pmol/L of 1,25(OH)2D.
The above highlight briefly how complex still remains the tempting prospect of including vitamin D supplements to the armamentarium of remedies for non-CF bronchiectasis. Among the many issues that have to be sufficiently addressed before any recommendations can be made, is to show that vitamin D supplementation is associated with measurable disease outcomes, define which patients would be benefited by this treatment, the serum levels that have to be attained, and the optimal doses. Physicians’ clinical decisions could be only assisted through carefully designed randomized controlled trials that will provide substantiated answers to above questions.
Vitamin D deficiency is associated with the risk for respiratory infectious diseases as it has been shown in epidemiological studies; additionally, vitamin D has a variety of immune-modulatory properties. Given the above, it is plausible to assume that there is an association between vitamin D deficiency and bronchiectasis. However, this association has been corroborated only in a single epidemiological study in adult population with non-CF bronchiectasis, and so it is premature to conclude causality. Nevertheless, the clarification of this issue is of great clinical importance. Maybe, in the light of new data, we have to reconsider the most appropriate doses and serum levels of vitamin D in CF. As for non-CF bronchiectasis, vitamin D supplementation could be an effective and safe option in the management of the disease, especially so because of the paucity of really effective treatment regimens.
Conflict-of-interest statement: The authors declare no conflict of interest.
Manuscript source: Invited manuscript
Specialty type: Pediatrics
Country of origin: Greece
Peer-review report classification
Grade A (Excellent): A
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
Peer-review started: January 11, 2017
First decision: February 20, 2017
Article in press: June 13, 2017
P- Reviewer: Jafari SA, Makishima M, Serban ED S- Editor: Kong JX L- Editor: A E- Editor: Lu YJ